Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will report fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, released before U.S. markets open.
The company will host a conference call and simultaneous webcast on January 30, 2026 at 8:30 AM Eastern Time. Investors may join the live webcast via Regeneron’s Investors and Media web page or register in advance to participate by telephone and receive dial-in details, a unique passcode, and registrant ID.
A replay and transcript will be archived on the company website for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – REGN
On Jan 5, the first trading day after this news, REGN closed 1.68% below the previous close.
Data tracked by StockTitan Argus for the Jan 5 session.
Key Figures
- Earnings release date
- January 30, 2026
- Q4 and full-year 2025 results release before U.S. market open
- Conference call time
- 8:30 AM Eastern Time
- Start time for Q4 and full-year 2025 results call
- Replay availability
- At least 30 days
- Archived webcast and transcript on company website
Historical Context
-
Dupixent approval in Japan for children 6–11 with severe asthma.
-
Announcement of presentation at 44th J.P. Morgan Healthcare Conference.
-
Positive Phase 1/2 Lynozyfic data in newly diagnosed multiple myeloma.
-
TSRA-196 gene-editing collaboration for AATD with Tessera Therapeutics.
-
EU approval of Dupixent for chronic spontaneous urticaria in patients 12+.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.